Clinical Trials Directory

Trials / Completed

CompletedNCT04170478

Transperineal Laser Ablation for Focal Treatment of Prostate Cancer

Transperineal Laser Ablation for Focal Prostate Cancer: Safety and Ablative Efficacy Evaluation Using Postradical Prostatectomy Histological Analysis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Academic / Other
Sex
Male
Age
40 Years
Healthy volunteers
Not accepted

Summary

Rationale: Prostate cancer (PCa) is the second cause of cancer-related deaths for men. The standard surgical treatment for localised prostate cancer is radical prostatectomy. Possible side effects of this treatment are incontinence and erectile dysfunction and this is related to the whole-gland resection. A focal treatment with fewer side effects is desired for patients with only a small focus of PCa. For this purpose, focal laser ablation is feasible. Current focal laser ablation techniques use a single fibre setup with the need for fibre replacement revisualisation of the tumour side accordingly. This leads to a long treatment duration. The Echolaser® system is a laser ablation system with four simultaneously operating laser sources. This provides a potential larger treatment area, without the need for fibre replacement. This makes the system advantageous for focal laser ablation of prostate cancer, especially since it can be applied under local anaesthesia. This pilot study aims to evaluate histological ablative efficacy on radical prostatectomy specimens following TPLA, feasibility and safety using a (multi)fibre setup in men with localized prostate cancer. The investigators hypothesize that TPLA will show adequate histological ablative efficacy and will be feasible and safe.

Conditions

Interventions

TypeNameDescription
DEVICEEcholaser X4 systemTransperineal laser ablation

Timeline

Start date
2020-08-01
Primary completion
2021-10-15
Completion
2021-10-15
First posted
2019-11-20
Last updated
2021-10-18

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT04170478. Inclusion in this directory is not an endorsement.